Advertisement

Head and Neck Cancer

  • Hubing Wu
  • Shaoli Song
Chapter

Abstract

Nasopharyngeal carcinoma (NPC) is a carcinoma arising from the nasopharyngeal mucosa and notorious for its highly malignant behavior, often presenting with intensive locoregional infiltration, regional lymph node metastasis, and distant metastasis. Radiotherapy is the most important treatment modality for NPC. As a sensitive imaging modality, 18F-FDG PET/CT plays an important role in diagnosing and staging of NPC, which is useful for making an individualized treatment for NPC patient.

References

  1. 1.
    El-Naggar AK, Chan JKC, Grandis JR et al (2017) WHO classification of head and neck tumours, 4th edn. The International Agency for Research on Cancer (IARC), Lyon Cedex, pp 65–70Google Scholar
  2. 2.
    Chinese Committee for Staging of Nasopharyngeal Carcinoma (2017) The 2017 edition for staging of nasopharyngeal carcinoma in China (The Chinese 2008 expert consensus on staging revision of nasopharyngeal carcinoma). Chin J Radiat Oncol 26(10):1119–1125. [Article in Chinese]Google Scholar
  3. 3.
    Hu-bing W, Quan-shi W, Ming-fang W et al (2005) The imaging manifestation and clinical value of PET/CT in nasopharyngeal carcinoma. Chin J Nucl Med 25:347–349. [Article in Chinese]Google Scholar
  4. 4.
    Ng SH, Chan SC, Yen TC et al (2009) Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up. Eur J Nucl Med Mol Imaging 36(1):12–22CrossRefGoogle Scholar
  5. 5.
    Liu FY, Lin CY, Chang JT et al (2007) 18F-FDG PET can replace conventional work-up in primary M staging of nonkeratinizing nasopharyngeal carcinoma. J Nucl Med 48(10):1614–1619CrossRefGoogle Scholar
  6. 6.
    King AD, Ma BB, Yau YY et al (2008) The impact of 18F-FDG PET/CT on assessment of nasopharyngeal carcinoma at diagnosis. Br J Radiol 81(964):291–298CrossRefGoogle Scholar
  7. 7.
    Chan SC, Yeh CH, Yen TC et al (2018) Clinical utility of simultaneous whole-body 18F-FDG PET/MRI as a single-step imaging modality in the staging of primary nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging 45(8):1297–1308CrossRefGoogle Scholar
  8. 8.
    Wu H-b, Wang Q-s, Wang M-f et al (2011) Preliminary study of 11C-choline PET/CT for T staging of locally advanced nasopharyngeal carcinoma: comparison with 18F-FDG PET/CT. J Nucl Med 52(3):341–346CrossRefGoogle Scholar
  9. 9.
    Ng SH, Chang JT, Chan SC et al (2004) Nodal metastases of nasopharyngeal carcinoma: patterns of disease on MRI and FDG PET. Eur J Nucl Med Mol Imaging 31(8):1073–1080CrossRefGoogle Scholar
  10. 10.
    Sun Y, Ma J, Lu TX et al (2004) Regulation for distribution of metastatic cervical lymph nodes of 512 cases of nasopharyngeal carcinoma. Ai Zheng 23(11 Suppl):1523–1527. [Article in Chinese]PubMedGoogle Scholar
  11. 11.
    Su Y, Zhao C, Xie CM et al (2006) Evaluation of CT, MRI and PET-CT in detecting retropharyngeal lymph node metastasis in nasopharyngeal carcinoma. Ai Zheng 25(5):521–525. [Article in Chinese]PubMedGoogle Scholar
  12. 12.
    Hu WH, Zhang GY, Liu LZ et al (2005) Comparison between PET-CT and MRI in diagnosing nodal metastasis of nasopharyngeal carcinoma. Ai Zheng 24(7):855–860. [Article in Chinese]PubMedGoogle Scholar
  13. 13.
    Lin XP, Zhao C, Chen MY et al (2008) Role of 18F-FDG PET/CT in diagnosis and staging of nasopharyngeal carcinoma. Ai Zheng 27(9):974–978PubMedGoogle Scholar
  14. 14.
    Peng H, Chen L, Tang LL et al (2017) Significant value of 18F-FDG-PET/CT in diagnosing small cervical lymph node metastases in patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy. Chin J Cancer 36(1):95CrossRefGoogle Scholar
  15. 15.
    Shen G, Zhang W, Jia Z et al (2014) Meta-analysis of diagnostic value of 18F-FDG PET or PET/CT for detecting lymph node and distant metastases in patients with nasopharyngeal carcinoma. Br J Radiol 87(1044):20140296CrossRefGoogle Scholar
  16. 16.
    Ren YY, Li YC, Wu HB et al (2017) Whole-body 18F-FDG PET/CT for M staging in the patient with newly diagnosed nasopharyngeal carcinoma: who needs? Eur J Radiol 89:200–207CrossRefGoogle Scholar
  17. 17.
    Gan H (2016) Guidelines for the clinical application of nuclear medicine and molecular imaging. People’s Health Press, Beijing, pp 65–70Google Scholar
  18. 18.
    Hu-bing W, Quan-shi W, Zhu-han H et al (2002) Clinical application of 18F-FDG PET in diagnosis and staging of patients with nasopharyngeal tumor. Chin J Nucl Med 22(4):137–138. [Article in Chinese]Google Scholar
  19. 19.
    Wei J, Pei S, Zhu X (2016) Comparison of 18F-FDG PET/CT, MRI and SPECT in the diagnosis of local residual/recurrent nasopharyngeal carcinoma: a meta-analysis. Oral Oncol 52:11–17CrossRefGoogle Scholar
  20. 20.
    Yen RF, Hong RL, Tzen KY et al (2005) Whole-body 18F-FDG PET in recurrent or metastatic nasopharyngeal carcinoma. J Nucl Med 46(5):770–774PubMedGoogle Scholar
  21. 21.
    Yen TC, Chang JT, Ng SH et al (2005) The value of 18F-FDG PET in the detection of stage M0 carcinoma of the nasopharynx. J Nucl Med 46(3):405–410PubMedGoogle Scholar
  22. 22.
    Chang MC, Chen JH, Liang JA et al (2013) Accuracy of whole-body FDG-PET and FDG-PET/CT in M staging of nasopharyngeal carcinoma: a systematic review and meta-analysis. Eur J Radiol 82(2):366–373CrossRefGoogle Scholar
  23. 23.
    Committee of Nasopharyngeal Cancer of Chinese Anti-Cancer Association, Xiaozhong C, Jingao L, Shaojun L, Chaosu H (2018) Expert consensus on the treatment of metastasis nasopharyngeal carcinoma. Chin J Radiat Oncol 27(1):7–15. [Article in Chinese].Google Scholar
  24. 24.
    Ng SH, Joseph CT, Chan SC et al (2004) Clinical usefulness of 18F-FDG PET in nasopharyngeal carcinoma patients with questionable MRI findings for recurrence. J Nucl Med 45(10):1669–1676PubMedGoogle Scholar
  25. 25.
    Gupta T, Master Z, Kannan S et al (2011) Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 38(11):2083–2095CrossRefGoogle Scholar
  26. 26.
    Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7–30CrossRefGoogle Scholar
  27. 27.
    Melroy CT, Senior BA (2006) Benign sinonasal neoplasms: a focus on inverting papilloma. Otolaryngol Clin North Am 39(3):601–617, x.CrossRefGoogle Scholar
  28. 28.
    Shojaku H, Fujisaka M, Yasumura S et al (2007) Positron emission tomography for predicting malignancy of sinonasal inverted papilloma. Clin Nucl Med 32(4):275–278CrossRefGoogle Scholar
  29. 29.
    Jeon TY, Kim HJ, Choi JY et al (2009) 18F-FDG PET/CT findings of sinonasal inverted papilloma with or without coexistent malignancy: comparison with MR imaging findings in eight patients. Neuroradiology 51(4):265–271CrossRefGoogle Scholar
  30. 30.
    Chang AE, Karnell LH, Menck HR (1998) The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 83(8):1664–1678CrossRefGoogle Scholar
  31. 31.
    Goerres GW, Stoeckli SJ, von Schulthess GK et al (2002) FDG PET for mucosal malignant melanoma of the head and neck. Laryngoscope 112(2):381–385CrossRefGoogle Scholar
  32. 32.
    Haerle SK, Soyka MB, Fischer DR et al (2012) The value of 18F-FDG-PET/CT imaging for sinonasal malignant melanoma. Eur Arch Otorhinolaryngol 269(1):127–133CrossRefGoogle Scholar
  33. 33.
    Roh JL, Yeo NK, Kim JS et al (2007) Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma. Oral Oncol 43(9):887–893CrossRefGoogle Scholar
  34. 34.
    Rusthoven KE, Koshy M, Paulino AC (2004) The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer 101(11):2641–2649CrossRefGoogle Scholar
  35. 35.
    Layland MK, Sessions DG, Lenox J (2005) The influence of lymph node metastasis in the treatment of squamous cell carcinoma of the oral cavity, oropharynx, larynx, and hypopharynx: N0 versus N+. Laryngoscope 115(4):629–639CrossRefGoogle Scholar
  36. 36.
    de Bree R, Castelijns JA, Hoekstra OS et al (2009) Advances in imaging in the work-up of head and neck cancer patients. Oral Oncol 45(11):930–935CrossRefGoogle Scholar
  37. 37.
    Senft A, de Bree R, Hoekstra OS et al (2008) Screening for distant metastases in head and neck cancer patients by chest CT or whole body FDG-PET: a prospective multicenter trial. Radiother Oncol 87(2):221–229CrossRefGoogle Scholar
  38. 38.
    Barbera L, Groome PA, Mackillop WJ et al (2001) The role of computed tomography in the T classification of laryngeal carcinoma. Cancer 91(2):394–407CrossRefGoogle Scholar
  39. 39.
    Cavaliere C, Romeo V, Aiello M et al (2017) Multiparametric evaluation by simultaneous PET-MRI examination in patients with histologically proven laryngeal cancer. Eur J Radiol 88:47–55CrossRefGoogle Scholar
  40. 40.
    Bertagna F, Albano D, Bosio G et al (2016) 18F-FDG-PET/CT in patients affected by differentiated thyroid carcinoma with positive thyroglobulin level and negative 131I whole body scan. It’s value confirmed by a bicentric experience. Curr Radiopharm 9(3):228–234CrossRefGoogle Scholar
  41. 41.
    Vera P, Kuhn-Lansoy C, Edet-Sanson A et al (2010) Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin? Thyroid 20(1):15–23CrossRefGoogle Scholar
  42. 42.
    Hassan A, Riaz S, Zafar W (2016) Fluorine-18 fluorodeoxyglucose avid thyroid incidentalomas on PET/CT scan in cancer patients: how sinister are they? Nucl Med Commun 37(10):1069–1073CrossRefGoogle Scholar
  43. 43.
    International Consortium for Outcome Research (ICOR) in Head and Neck Cancer, Ebrahimi A et al (2014) Primary tumor staging for oral cancer and a proposed modification incorporating depth of invasion: an international multicenter retrospective study. JAMA Otolaryngol Head Neck Surg 140(12):1138–1148CrossRefGoogle Scholar
  44. 44.
    Youngwirth LM, Adam MA, Scheri RP et al (2017) Extrathyroidal extension is associated with compromised survival in patients with thyroid cancer. Thyroid 27(5):626–631CrossRefGoogle Scholar
  45. 45.
    Perrier ND, Brierley JD, Tuttle RM (2018) Differentiated and anaplastic thyroid carcinoma: major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 68(1):55–63CrossRefGoogle Scholar
  46. 46.
    Wong RJ, Lin DT, Schoder H et al (2002) Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 20(20):4199–4208CrossRefGoogle Scholar
  47. 47.
    Zbaren P, Nuyens M, Curschmann J et al (2007) Histologic characteristics and tumor spread of recurrent glottic carcinoma: analysis on whole-organ sections and comparison with tumor spread of primary glottic carcinomas. Head Neck 29(1):26–32CrossRefGoogle Scholar
  48. 48.
    Robin P, Abgral R, Valette G et al (2015) Diagnostic performance of FDG PET/CT to detect subclinical HNSCC recurrence 6 months after the end of treatment. Eur J Nucl Med Mol Imaging 42(1):72–78CrossRefGoogle Scholar
  49. 49.
    Becker M, Varoquaux AD, Combescure C et al (2018) Local recurrence of squamous cell carcinoma of the head and neck after radio(chemo)therapy: diagnostic performance of FDG-PET/MRI with diffusion-weighted sequences. Eur Radiol 28(2):651–663CrossRefGoogle Scholar
  50. 50.
    Zimmer LA, Snyderman C, Fukui MB et al (2005) The use of combined PET/CT for localizing recurrent head and neck cancer: the Pittsburgh experience. Ear Nose Throat J 84(2):104, 106, 108–110CrossRefGoogle Scholar
  51. 51.
    Gilbert MR, Branstetter BF, Kim S (2012) Utility of positron-emission tomography/computed tomography imaging in the management of the neck in recurrent laryngeal cancer. Laryngoscope 122(4):821–825CrossRefGoogle Scholar
  52. 52.
    Rosko A, Birkeland A, Shuman A et al (2017) Positron emission tomography-CT prediction of occult nodal metastasis in recurrent laryngeal cancer. Head Neck 39(5):980–987CrossRefGoogle Scholar
  53. 53.
    Zimmer LA, McCook B, Meltzer C et al (2003) Combined positron emission tomography/computed tomography imaging of recurrent thyroid cancer. Otolaryngol Head Neck Surg 128(2):178–184CrossRefGoogle Scholar
  54. 54.
    Kim SK, So Y, Chung HW et al (2016) Analysis of predictability of F-18 fluorodeoxyglucose-PET/CT in the recurrence of papillary thyroid carcinoma. Cancer Med 5(10):2756–2762CrossRefGoogle Scholar
  55. 55.
    Kim SY, Roh JL, Yeo NK et al (2007) Combined 18F-fluorodeoxyglucose-positron emission tomography and computed tomography as a primary screening method for detecting second primary cancers and distant metastases in patients with head and neck cancer. Ann Oncol 18(10):1698–1703CrossRefGoogle Scholar
  56. 56.
    Rohde M, Nielsen AL, Johansen J et al (2017) Head-to-head comparison of chest X-ray/head and neck MRI, chest CT/head and neck MRI, and (18)F-FDG PET/CT for detection of distant metastases and synchronous cancer in oral, pharyngeal, and laryngeal cancer. J Nucl Med 58(12):1919–1924CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. and Shanghai Jiao Tong University Press 2019

Authors and Affiliations

  • Hubing Wu
    • 1
  • Shaoli Song
    • 2
  1. 1.Nanfang PET center, Nanfang Hospital, Southern Medical UniversityGuangzhouP. R. China
  2. 2.Department of Nuclear MedicineFudan University Shanghai Cancer HospitalShanghaiP. R. China

Personalised recommendations